ARWR

Over the past six months (April to October 2026), Arrowhead Pharmaceuticals released its Q2 2026 earnings on May 7, 2026, and Q3 2026 earnings on August 4, 2026, reporting a loss of ($1.36) per share for Q3, missing estimates. An Annual General Meeting was held on March 19, 2026. On October 7, 2026, plozasiran was granted entry into the U.S. FDA's Split Real Time Application Review (STAR) pilot program for severe hypertriglyceridemia, with positive topline results from Phase 3 SHASTA-3 and SHASTA-4 studies showing significant triglyceride reductions and a reduction in acute pancreatitis events, leading to the acquisition of a priority review voucher. The U.S. launch of REDEMPLO continued to gain momentum, with prescription volume roughly doubling in Q3 2026, over 400 unique prescribers, and favorable payer policies. Goldman Sachs resumed coverage of ARWR with a $74 target in September 2026. The stock price on October 5, 2026, was $62.35 per share, with a 52-week range of $34.61 to $95.49, and a 77.21 percent increase over the last 12 months.